Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR 206.00
+2.00 (0.98%)
Inactive · Last trade price on Apr 17, 2026
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 246.60M EUR in the quarter ending March 31, 2026, with 144.27% growth. This brings the company's revenue in the last twelve months to 865.78M, up 134.82% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
865.78M
Revenue Growth
+134.82%
P/S Ratio
16.91
Revenue / Employee
605.66K
Employees
1,189
Market Cap
12.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAscendis Pharma News
- 12 days ago - Ascendis Pharma price target raised to $280 from $275 at RBC Capital - TheFly
- 18 days ago - 14 value stocks of companies primed for rapid growth through 2028 - Market Watch
- 19 days ago - Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TheFly
- 19 days ago - Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial - GlobeNewsWire
- 22 days ago - Ascendis Pharma added to multiple Russell U.S. Indexes - TheFly
- 22 days ago - Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® - GlobeNewsWire
- 23 days ago - Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma completes Phase 3 PaTHway Trial - TheFly